-
Vascular Health and Risk Management
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers
Original Research
(4543) Total Article Views
Authors: André C Schmidt, Burkhard Flick, Elke Jahn, Peter Bramlage
Published Date September 2008 Volume 2008:4(4) Pages 905 - 915
DOI: http://dx.doi.org/10.2147/VHRM.S3020
André C Schmidt1, Burkhard Flick1, Elke Jahn2, Peter Bramlage3
1Charité – Universitätsmedizin Berlin, Institute for Clinical Pharmacology and Toxikology, Berlin, Germany; 2Berlin-Chemie AG, Clinical Research and Medical Information, Berlin, Germany; 3Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, TU Dresden, Germany
Objective: To assess the effect of nebivolol, a highly selective third generation β1-adrenoceptor antagonist with an endothelium-dependent vasodilatory action, on smoking-induced endothelial dysfunction.
Research design and methods: This open-label study examined the effect of 14 daily doses of 5 mg nebivolol on forearm blood flow in 21 healthy, young, male, light smokers (≤5 cigarettes/day), measured by plethysmography on Days 1, 7, and 14. The primary endpoint was the difference in forearm blood flow after smoking one standard cigarette from baseline (Day 1) until treatment end on Day 14. Secondary outcomes included the difference in forearm blood flow between Day 1 and Day 7 compared with Day 14 before and after smoking, the effect of nebivolol on blood coagulation parameters, high-sensitive-C-reactive protein (hs-CRP), and the safety and tolerability of nebivolol.
Results: Nebivolol for 14 days did not significantly affect forearm blood flow after smoking. On Day 7 of nebivolol treatment, forearm blood flow after smoking was significantly greater than blood flow before smoking (increase of 0.44 mL/min; p = 0.00656). Serum level of hs-CRP showed a marked decrease from Day 1 to Day 14. No changes in coagulation parameters were observed over the course of nebivolol treatment. Nebivolol was well tolerated throughout the study.
Conclusions: The increase in forearm blood flow and the marked decrease in hs-CRP over 14 days of treatment suggest that nebivolol has a positive effect on endothelial function in light smokers, but larger studies are required to confirm these observations.
Keywords: C-reactive protein, endothelial dysfunction, nebivolol, nitric oxide (NO), smoking
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- ACC 2014
We will attend the 2014 American College of Cardiology Scientific Session and Expo (ACC) on March 29-31, 2014. Stop by booth 3217 to talk with us.
- Like us on Facebook
Click the blue link above to become a part of our Facebook community.
- The western diet and lifestyle and diseases of civilization
- Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
- Everolimus-eluting stents in interventional cardiology
- Transitioning from population to individualized preventive cardiology